{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T14:22:56Z","timestamp":1781706176699,"version":"3.54.5"},"reference-count":28,"publisher":"Society of Nuclear Medicine","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2025,1,17]]},"published-print":{"date-parts":[[2025,4]]},"DOI":"10.2967\/jnumed.124.268639","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T17:40:26Z","timestamp":1740073226000},"page":"531-536","source":"Crossref","is-referenced-by-count":6,"title":["PSMA-Guided Metastasis-Directed Therapy for Oligometastatic Renal Cell Carcinoma: The Proof-of-Concept PEDESTAL Study"],"prefix":"10.2967","volume":"66","author":[{"given":"Cristian","family":"Udovicich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Bressel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamil","family":"Manji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis","family":"Au","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun A.","family":"Azad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James P.","family":"Buteau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarat","family":"Chander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renu","family":"Eapen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Lawrentschuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidney M.","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Declan G.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlon","family":"Perera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lavinia","family":"Spain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Hofman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shankar","family":"Siva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2025,2,20]]},"reference":[{"key":"2025040211001540000_66.4.531.1","doi-asserted-by":"crossref","first-page":"e2021869","DOI":"10.1001\/jamanetworkopen.2020.21869","article-title":"Evaluation of clear cell, papillary, and chromophobe renal cell carcinoma metastasis sites and association with survival","volume":"4","author":"Dudani","year":"2021","journal-title":"JAMA Netw Open."},{"key":"2025040211001540000_66.4.531.2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.6.2261"},{"key":"2025040211001540000_66.4.531.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2010.09.086"},{"key":"2025040211001540000_66.4.531.4","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S1470-2045(24)00020-2","article-title":"Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial","volume":"25","author":"Siva","year":"2024","journal-title":"Lancet Oncol."},{"key":"2025040211001540000_66.4.531.5","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.euo.2019.05.007","article-title":"Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): a meta-analysis of 28 studies","volume":"2","author":"Zaorsky","year":"2019","journal-title":"Eur Urol Oncol."},{"key":"2025040211001540000_66.4.531.6","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/S1470-2045(21)00528-3","article-title":"Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial","volume":"22","author":"Tang","year":"2021","journal-title":"Lancet Oncol."},{"key":"2025040211001540000_66.4.531.7","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.eururo.2021.12.006","article-title":"Stereotactic radiotherapy and short-course pembrolizumab for oligometastatic renal cell carcinoma: the rapport trial","volume":"81","author":"Siva","year":"2022","journal-title":"Eur Urol."},{"key":"2025040211001540000_66.4.531.8","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.eururo.2021.07.026","article-title":"Stereotactic radiotherapy for oligoprogression in metastatic renal cell cancer patients receiving tyrosine kinase inhibitor therapy: a phase 2 prospective multicenter study","volume":"80","author":"Cheung","year":"2021","journal-title":"Eur Urol."},{"key":"2025040211001540000_66.4.531.9","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.euo.2021.12.001","article-title":"Phase II trial of stereotactic ablative radiation for oligoprogressive metastatic kidney cancer","volume":"5","author":"Hannan","year":"2022","journal-title":"Eur Urol Oncol."},{"key":"2025040211001540000_66.4.531.10","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.euo.2022.06.008","article-title":"Stereotactic ablative radiation for systemic therapy-na\u00efve oligometastatic kidney cancer","volume":"5","author":"Hannan","year":"2022","journal-title":"Eur Urol Oncol."},{"key":"2025040211001540000_66.4.531.11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-2083"},{"key":"2025040211001540000_66.4.531.12","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.euros.2022.08.001","article-title":"Impact of prostate-specific membrane antigen positron emission tomography\/computed tomography in the management of oligometastatic renal cell carcinoma","volume":"44","author":"Udovicich","year":"2022","journal-title":"Eur Urol Open Sci."},{"key":"2025040211001540000_66.4.531.13","first-page":"2674","article-title":"Prostate-specific membrane antigen is produced in tumor-associated neovasculature","volume":"5","author":"Chang","year":"1999","journal-title":"Clin Cancer Res."},{"key":"2025040211001540000_66.4.531.14","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","article-title":"The Lancet Commission on prostate cancer: planning for the surge in cases","volume":"403","author":"James","year":"2024","journal-title":"Lancet."},{"key":"2025040211001540000_66.4.531.15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30314-7"},{"key":"2025040211001540000_66.4.531.16","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.eururo.2022.06.017","article-title":"The role of stereotactic ablative body radiotherapy in renal cell carcinoma","volume":"82","author":"Ali","year":"2022","journal-title":"Eur Urol."},{"key":"2025040211001540000_66.4.531.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"2025040211001540000_66.4.531.18","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s00259-023-06380-4","article-title":"Clinical impact of prostate-specific membrane antigen positron emission tomography (PET) on intensification or deintensification of advanced renal cell carcinoma management","volume":"51","author":"Pathmanathan","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025040211001540000_66.4.531.19","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.ijrobp.2022.05.034","article-title":"Impact of medical operability and total metastatic ablation on outcomes after SABR for oligometastases","volume":"114","author":"Siva","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"2025040211001540000_66.4.531.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312695"},{"key":"2025040211001540000_66.4.531.21","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA. Oncol."},{"key":"2025040211001540000_66.4.531.22","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.267586"},{"key":"2025040211001540000_66.4.531.23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035716"},{"key":"2025040211001540000_66.4.531.24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1712126"},{"key":"2025040211001540000_66.4.531.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2018.04.028"},{"key":"2025040211001540000_66.4.531.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2005.03.022"},{"key":"2025040211001540000_66.4.531.27","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.267175"},{"key":"2025040211001540000_66.4.531.28","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.267417"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.124.268639","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T18:07:44Z","timestamp":1743617264000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.124.268639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,20]]},"references-count":28,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4,1]]},"published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.2967\/jnumed.124.268639"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.124.268639","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,20]]}}}